Anorexia NervosaNCT05290285
Amino Acids in Patients With Anorexia Nervosa: Double-blind Randomized Study Versus Placebo
A study testing Amino-Ther Pro in people with Anorexia Nervosa, run by Villa Garda Hospital at 1 site in Italy.
Trial summary
Amino acids (AAs) are crucial for protein synthesis, in influencing nutritional status, as sources of vital elements (e.g., nucleotides, neurotransmitters) and as signal molecules for the modulation of gene expression and epigenetic mechanisms. Read more about this study
- Who is it for?
- Ages 16 to 50 years
- Conditions the study is for
- Anorexia Nervosa
- What is being tested?
- Amino-Ther Pro
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 92 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jul 2022to 1 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 50 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Diagnosis of anorexia nervosa
- Age between 16 and 50 years
- Written informed consent
Who cannot join
- Schizophrenia or other psychotic disorders
- Diagnosis of bulimia nervosa
- Current and ongoing substance use disorder
- Medical complications capable of hindering the interpretation of the results (e.g. a a medical disease that induces weight loss)
- Presence of physical treatments (including drugs) hindering the interpretation of the results (e.g. chemotherapy for cancer)
- Being pregnant or intending to become pregnant during treatment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Department of Eating and Weight Disorders, Villa Garda Hospital
Garda, Italy, 37016
Riccardo Dalle Grave, MD, 0039 3484120680 ext. 0039, rdalleg@gmail.com
About this study
Official title: Efficacy and Tolerability of a Specific Blend of Amino Acids in Patients With Anorexia Nervosa Treated in a Hospital Setting. Double-blind Randomized Study Versus Placebo
Amino acids (AAs) are crucial for protein synthesis, in influencing nutritional status, as sources of vital elements (e.g., nucleotides, neurotransmitters) and as signal molecules for the modulation of gene expression and epigenetic mechanisms. Data on the role of amino acids in underweight patients with anorexia nervosa (AN) are unknown. This study aims to evaluate whether a blend of essential amino acids (EAA) could influence the change in lean body mass (LBM) in patients with AN during weight restoration, treated with intensive inpatient enhanced cognitive behavior therapy (CBT-E). A total of 92 patients will be randomized to EAA supplementation or placebo supplementation upon admission to inpatient treatment. LBM, but also body weight, specific and general psychopathology, impairment assessment will be assessed at baseline and after 13 weeks of treatment.
Read the detailed description
Nutrition is one of the main determinants of health. Among the three primary macronutrients, proteins - specifically, their quantity and quality (i.e., their specific amino acid profile) - play a crucial role in regulating metabolic health and longevity. Amino acids (AAs) are crucial not only for protein synthesis and influencing nutritional status but also as sources of vital elements (e.g., nucleotides, neurotransmitters) and as signal molecules for the modulation of gene expression and epigenetic mechanisms. To our knowledge, only one study was conducted on underweight patients with anorexia nervosa (AN). The study design was to compare the efficacy of the semi-essential amino acid L-tyrosine (100 mg/kg/day) versus a placebo supplement. Tyrosine reduced reaction time and test duration in memory tasks and improved mood. However, to date, no studies have evaluated the effect of supplementation with amino acids in patients with anorexia nervosa who undergo specialist treatment aimed at weight recovery and remission from psychopathology.
The study has the primary aim of evaluating the effectiveness of supplementation with essential amino acids (EAA) on the change in lean body mass (LBM) with weight recovery in patients with AN treated with specialist treatment for eating disorders, compared to placebo supplementation. The secondary aims of the study are to evaluate the effectiveness of EAA supplementation on physical fitness, weight recovery, change of the general and eating disorder psychopathology, and psychosocial impairment, compared to placebo supplementation.
A 13-week randomized double-blind placebo-controlled study design will be used.
Patients will be randomized to EAA supplementation or placebo supplementation upon admission. Randomization will be carried out by an independent external figure adopting the following stratification:
Group 1: Body Mass Index (BMI) <= 15.2 \& age <= 20 Group 2: BMI > 15.2 \& age <= 20 Group 3: BMI <= 15.2 \& age > 20 Group 4: BMI > 15.2 \& age > 20 Treatment will involve a 13-week inpatient or a 13-week day hospital. Follow-up will be performed for both groups at 24 weeks. Considering that it will not be possible to carry out a closed follow-up, we will give the possibility to those who have taken the mixture of EAA to continue this treatment after the end of inpatient or day-hospital, for other 24 weeks, to evaluate the potential long-term maintenance of the treatment.
The study is performed at the Nutritional Rehabilitation Unit of the Villa Garda Hospital - Italy.
The supervision of the diagnostic evaluation and treatment is carried out weekly by the Director of the Nutritional Rehabilitation Unit of the Villa Garda Hospital.
Study participants will be recruited from patients who meet the diagnostic criteria for AN, assessed with the Eating Disorder Examination (EDE.17) interview, consecutively admitted at the Nutritional Rehabilitation Unit of the Villa Garda Hospital. All participants will meet the appropriateness criteria of hospitalization established by the Veneto Region and described in table 1 of Annex B of DGR 94/2012.
On the entry day into the Nutritional Rehabilitation Unit, the patient will meet a unit physician for the medical history collection, the physical examination, and the prescription of humoral and instrumental examinations. On this occasion, the enrollment phase will take place which will include the complete collection of data for the compilation of the Data Collection Form. At the end of the data collection, if the criteria for inclusion in the study are met, the patient will receive detailed information on:
- Procedures and objectives of the study
- Purposes, methods, inconveniences, risks, and benefits that the study may entail
- Freedom to participate and withdraw from the study without affecting subsequent treatment
- Compensation procedures and treatment of any damages deriving from participation in the study.
Before requesting to sign the informed consent and the possibility of using (and having consent to use) the information collected during the trial, the patient will be given a statement to read containing detailed information on the study.
If the patient, or in the case of a minor patient, his/her parents (s), and/or legal guardians (s), agrees to participate in the study, he/she will sign the informed consent form and the authorization to process personal and sensitive data.
If the patient meets the criteria for inclusion in the study but refuses to participate in the study, he/she will continue the intensive rehabilitation treatment applied at the Nutritional Rehabilitation Unit of the Villa Garda Hospital.
After the interview and signing the informed consent and data processing, the patient will be randomized to EAA supplementation or placebo supplementation. Both arms will receive enhanced cognitive behavior therapy (CBT-E).
The intensive CBT-E applied at the Nutritional Rehabilitation Unit of the Villa Garda Hospital has been described in national and international publications. The treatment is based on the transdiagnostic cognitive-behavioral theory and therapy of eating disorders developed by the Center for Research on Eating Disorders and Obesity of the University of Oxford.
The inpatient treatment includes 13 weeks, followed by seven weeks of day-hospital, and is divided into four phases that are individualized to address the maintenance mechanisms of the eating disorder psychopathology operating in the individual patient.
- Phase One - Starting Well. This phase aims to engage the patient, educate him about his eating disorder, build the Personalized Formulation, start the collaborative weight measurement and use the Monitoring Records and the Eating Problem Check List (EPCL) questionnaire. During this phase, the patient is encouraged to make maximum behavioral change, including starting the weight regain process, if indicated.
- Phase Two. In this phase, a formal assessment of the progress and obstacles to change and of the possible presence of external maintenance mechanisms is performed to plan the next phase of treatment.
- Phase Three. The precise content of this phase is dictated by the specific psychopathology operating in the patient and the treatment becomes very individualized. In typical cases, negative body image, calorie and cognitive dietary restriction, events and emotions affecting nutrition, and, in a subset of patients, one or more of the external maintenance mechanisms identified in Phase Two are addressed in specific modules of the extended version of the treatment. At this stage, the underweight patient in most cases reaches his BMI goal and starts practicing weight maintenance. Towards the end of this phase, backward steps and mental states are also addressed to learn to decentralize oneself from the mental state of the eating disorder, to prevent relapse.
- Phase Four - Ending Well. This phase aims to conclude the treatment well and prepare the transition to outpatient therapy. For this purpose, a written maintenance plan is created, in collaboration with the patient, in which the residual problems are to be faced and the procedures to continue to be used, the strategies and methods to prevent relapse, the ways of organizing life after discharge and post-admission therapy.
The nutritional rehabilitation protocol of the Villa Garda Hospital applied to underweight patients with AN is as follows:
- The weight goal to be achieved is a BMI ≥ 19.
- The expected speed of weight recovery is between 1 and 1.5 kg per week.
- The daily calorie content of the meal plan is established collaboratively with the patient in the first as follows:
- Week 1: Menu A (1,500 kcal)
- Week 2: Menu B (2,000 kcal)
Afterward:
- If the weight increases between 1 and 1.5 kg per week the meal plan is maintained with the same calorie content as the previous week.
- If the weight increases by less than 1 kg per week, the kcal of the food plan is increased by 500 kcal per day. For example, from Menu B to Menu C (2500 kcal) or from Menu C to Menu D (3000 kcal)
- If the weight increases by more than 1.5 kg per week, the kcal of the food plan must be reduced by 250 kcal per day. For example, from Menu C to Menu B / C (2250 kcal)
- When the patient reaches a BMI of 19, the goal of the program is to identify a weight range of 3 kg that it can be without adopting a calorie dietary restriction. In most patients, weight maintenance occurs with a diet between 2000 (Menu B) and 2500 kcal (Menu C).
- Physical activity proposed in the rehabilitation program All patients above the BMI of 15 do two 30-minute sessions per week of calisthenics followed by a physiotherapist.
- Conditions
- Anorexia Nervosa
- Being tested
- Amino-Ther Pro, Placebo
- Keywords
- lean body mass, amino-acids
- Medical subject headings
- Anorexia Nervosa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Amino-Ther ProDietary supplement
Food supplements
PlaceboDietary supplement
Maltodextrin
| Study group | Role | What they receive |
|---|---|---|
| EAA supplementation | Experimental | The EAA blend consists of a complex blend of essential amino acids, including some precursors of neurotransmitters that are important for regulating mood. In particular, phenylalanine, a precursor of tyrosine (non-essential amino acid) is involved in the biosynthesis of catecholamines (noradrenaline, adrenaline, dopamine) and tryptophan is the precursor of serotonin. Furthermore, the amino acids present in the mixture and the precursors of the Krebs cycle (citrate, malate, succinate) are able to stimulate mitochondrial bioenergetics by improving metabolism and muscle function.
The EAA blend will be administered orally at 4.5 g twice daily (two sachets of Amino-Ther Pro per day). Receives: Dietary Supplement: Amino-Ther Pro |
| Placebo | Placebo comparator | Placebo is an isocaloric product containing maltodextrins instead of amino acids (Acquilani et al., 2011). The placebo will be administered orally 4.5 g twice daily. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lean body mass
Percentage change in patient's lean body mass with weight gain at the end of hospital treatment, measured using the DXA (Prodigy Primo Lunar, A223040501, General Electric Company, Madison. WI 53707-7550, USA-EnCORE TM 2009 (v13.31) software)
Measured: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Secondary outcomes (5)
Physical fitness
Change in physical fitness measured using the Eurofit Physical Fitness Test Battery (EPFTB) (EUROFIT Strasbourg: Council of Europe; 1993
Measured: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Body weight
Change in body weight measured using the Seca Digital Wheelchair Scale Model 664 [Seca, Hamburg, Germany]
Measured: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Eating disorder psychopathology
Change in eating disorder psychopathology measured using the Eating Disorder Examination Questionnaire (EDE-Q) (Calugi, Milanese, et al., 2017; Fairburn \& Beglin, 2008).
Measured: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
General psychopathology
Change in general psychopathology measured using the Brief Symptom Inventory (BSI) (De Leo, Frisoni, Rozzini, \& Trabucchi, 1993; Derogatis \& Spencer, 1982).
Measured: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Clinical impairment
Change in clinical impairment measured using the Clinical Impairment Assessment (CIA) (Bohn et al., 2008; Calugi et al., 2018).
Measured: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2022
- Study start1 Jul 2022
- Primary completion1 Jan 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Anorexia NervosaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A 13-week randomized double-blind placebo-controlled study. Patients will be randomized to EAA supplementation or placebo supplementation upon admission. Randomisation will be carried out by an independent external figure adopting the following stratification: Group 1: BMI \<= 15.2 \& age \<= 20 Group 2: BMI \> 15.2 \& age \<= 20 Group 3: BMI \<= 15.2 \& age \> 20 Group 4: BMI \> 15.2 \& age \> 20
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 92 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Villa Garda Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Milan, Università degli Studi di Brescia
- Responsible party
- Principal investigator, Riccardo Dalle Grave, Villa Garda Hospital
- Investigators
- Riccardo Dalle Grave, MD, Principal investigator, Villa Garda Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05290285
- Sponsor's protocol ID
- ATAN/22
- Status last verified
- Aug 2025
- First submitted
- 11 Mar 2022
- Last updated
- 5 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data are not available for privacy reasons
Publications
Dalle Grave R, Calugi S, Conti M, Doll H, Fairburn CG. Inpatient cognitive behaviour therapy for anorexia nervosa: a randomized controlled trial. Psychother Psychosom. 2013;82(6):390-8. doi: 10.1159/000350058. Epub 2013 Sep 20.
PubMed 24060628El Ghoch M, Pourhassan M, Milanese C, Muller MJ, Calugi S, Bazzani PV, Dalle Grave R. Changes in lean and skeletal muscle body mass in adult females with anorexia nervosa before and after weight restoration. Clin Nutr. 2017 Feb;36(1):170-178. doi: 10.1016/j.clnu.2015.10.006. Epub 2015 Oct 28.
PubMed 26560758Buondonno I, Sassi F, Carignano G, Dutto F, Ferreri C, Pili FG, Massaia M, Nisoli E, Ruocco C, Porrino P, Ravetta C, Riganti C, Isaia GC, D'Amelio P. From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study. Clin Nutr. 2020 Jul;39(7):2080-2091. doi: 10.1016/j.clnu.2019.10.013. Epub 2019 Oct 18.
PubMed 31672329Israely M, Ram A, Brandeis R, Alter Z, Avraham Y, Berry EM. A Double Blind, Randomized Cross-Over Trial of Tyrosine Treatment on Cognitive Function and Psychological Parameters in Severe Hospitalized Anorexia Nervosa Patients. Isr J Psychiatry. 2017;54(3):52-58.
PubMed 29735813Fairburn CG, Cooper Z, Shafran R. Cognitive behaviour therapy for eating disorders: a "transdiagnostic" theory and treatment. Behav Res Ther. 2003 May;41(5):509-28. doi: 10.1016/s0005-7967(02)00088-8.
PubMed 12711261Dalle Grave R, Calugi S, Ruocco C, Chimini M, Segala A, Ragni M, Carruba M, Valerio A, Nisoli E. Efficacy and tolerability of a specific blend of amino acids in patients with anorexia nervosa treated in a hospital setting: study protocol for a randomized controlled trial. Trials. 2023 Feb 9;24(1):104. doi: 10.1186/s13063-023-07120-7.
PubMed 36759873
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Tolerability of a Specific Blend of Amino Acids in Patients With Anorexia Nervosa Treated in a Hospital Setting. Double-blind Randomized Study Versus Placebo
- ClinicalTrials.gov ID
- NCT05290285
- Acronym / sponsor ID
- ATAN/22
- Conditions
- Anorexia Nervosa
- Keywords
- lean body mass, amino-acids
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 92 participants (estimated)
- Lead sponsor
- Villa Garda HospitalUniversity, hospital or other
- Collaborators
- University of Milan, Università degli Studi di Brescia
- Study start
- 1 Jul 2022 (actual)
- Primary completion
- 1 Jan 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 22 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Amino acids (AAs) are crucial for protein synthesis, in influencing nutritional status, as sources of vital elements (e.g., nucleotides, neurotransmitters) and as signal molecules for the modulation of gene expression and epigenetic mechanisms. Data on the role of amino acids in underweight patients with anorexia nervosa (AN) are unknown. This study aims to evaluate whether a blend of essential amino acids (EAA) could influence the change in lean body mass (LBM) in patients with AN during weight restoration, treated with intensive inpatient enhanced cognitive behavior therapy (CBT-E). A total of 92 patients will be randomized to EAA supplementation or placebo supplementation upon admission to inpatient treatment. LBM, but also body weight, specific and general psychopathology, impairment assessment will be assessed at baseline and after 13 weeks of treatment.
Detailed description
Nutrition is one of the main determinants of health. Among the three primary macronutrients, proteins - specifically, their quantity and quality (i.e., their specific amino acid profile) - play a crucial role in regulating metabolic health and longevity. Amino acids (AAs) are crucial not only for protein synthesis and influencing nutritional status but also as sources of vital elements (e.g., nucleotides, neurotransmitters) and as signal molecules for the modulation of gene expression and epigenetic mechanisms. To our knowledge, only one study was conducted on underweight patients with anorexia nervosa (AN). The study design was to compare the efficacy of the semi-essential amino acid L-tyrosine (100 mg/kg/day) versus a placebo supplement. Tyrosine reduced reaction time and test duration in memory tasks and improved mood. However, to date, no studies have evaluated the effect of supplementation with amino acids in patients with anorexia nervosa who undergo specialist treatment aimed at weight recovery and remission from psychopathology.
The study has the primary aim of evaluating the effectiveness of supplementation with essential amino acids (EAA) on the change in lean body mass (LBM) with weight recovery in patients with AN treated with specialist treatment for eating disorders, compared to placebo supplementation. The secondary aims of the study are to evaluate the effectiveness of EAA supplementation on physical fitness, weight recovery, change of the general and eating disorder psychopathology, and psychosocial impairment, compared to placebo supplementation.
A 13-week randomized double-blind placebo-controlled study design will be used.
Patients will be randomized to EAA supplementation or placebo supplementation upon admission. Randomization will be carried out by an independent external figure adopting the following stratification:
Group 1: Body Mass Index (BMI) <= 15.2 \& age <= 20 Group 2: BMI > 15.2 \& age <= 20 Group 3: BMI <= 15.2 \& age > 20 Group 4: BMI > 15.2 \& age > 20 Treatment will involve a 13-week inpatient or a 13-week day hospital. Follow-up will be performed for both groups at 24 weeks. Considering that it will not be possible to carry out a closed follow-up, we will give the possibility to those who have taken the mixture of EAA to continue this treatment after the end of inpatient or day-hospital, for other 24 weeks, to evaluate the potential long-term maintenance of the treatment.
The study is performed at the Nutritional Rehabilitation Unit of the Villa Garda Hospital - Italy.
The supervision of the diagnostic evaluation and treatment is carried out weekly by the Director of the Nutritional Rehabilitation Unit of the Villa Garda Hospital.
Study participants will be recruited from patients who meet the diagnostic criteria for AN, assessed with the Eating Disorder Examination (EDE.17) interview, consecutively admitted at the Nutritional Rehabilitation Unit of the Villa Garda Hospital. All participants will meet the appropriateness criteria of hospitalization established by the Veneto Region and described in table 1 of Annex B of DGR 94/2012.
On the entry day into the Nutritional Rehabilitation Unit, the patient will meet a unit physician for the medical history collection, the physical examination, and the prescription of humoral and instrumental examinations. On this occasion, the enrollment phase will take place which will include the complete collection of data for the compilation of the Data Collection Form. At the end of the data collection, if the criteria for inclusion in the study are met, the patient will receive detailed information on:
- Procedures and objectives of the study
- Purposes, methods, inconveniences, risks, and benefits that the study may entail
- Freedom to participate and withdraw from the study without affecting subsequent treatment
- Compensation procedures and treatment of any damages deriving from participation in the study.
Before requesting to sign the informed consent and the possibility of using (and having consent to use) the information collected during the trial, the patient will be given a statement to read containing detailed information on the study.
If the patient, or in the case of a minor patient, his/her parents (s), and/or legal guardians (s), agrees to participate in the study, he/she will sign the informed consent form and the authorization to process personal and sensitive data.
If the patient meets the criteria for inclusion in the study but refuses to participate in the study, he/she will continue the intensive rehabilitation treatment applied at the Nutritional Rehabilitation Unit of the Villa Garda Hospital.
After the interview and signing the informed consent and data processing, the patient will be randomized to EAA supplementation or placebo supplementation. Both arms will receive enhanced cognitive behavior therapy (CBT-E).
The intensive CBT-E applied at the Nutritional Rehabilitation Unit of the Villa Garda Hospital has been described in national and international publications. The treatment is based on the transdiagnostic cognitive-behavioral theory and therapy of eating disorders developed by the Center for Research on Eating Disorders and Obesity of the University of Oxford.
The inpatient treatment includes 13 weeks, followed by seven weeks of day-hospital, and is divided into four phases that are individualized to address the maintenance mechanisms of the eating disorder psychopathology operating in the individual patient.
- Phase One - Starting Well. This phase aims to engage the patient, educate him about his eating disorder, build the Personalized Formulation, start the collaborative weight measurement and use the Monitoring Records and the Eating Problem Check List (EPCL) questionnaire. During this phase, the patient is encouraged to make maximum behavioral change, including starting the weight regain process, if indicated.
- Phase Two. In this phase, a formal assessment of the progress and obstacles to change and of the possible presence of external maintenance mechanisms is performed to plan the next phase of treatment.
- Phase Three. The precise content of this phase is dictated by the specific psychopathology operating in the patient and the treatment becomes very individualized. In typical cases, negative body image, calorie and cognitive dietary restriction, events and emotions affecting nutrition, and, in a subset of patients, one or more of the external maintenance mechanisms identified in Phase Two are addressed in specific modules of the extended version of the treatment. At this stage, the underweight patient in most cases reaches his BMI goal and starts practicing weight maintenance. Towards the end of this phase, backward steps and mental states are also addressed to learn to decentralize oneself from the mental state of the eating disorder, to prevent relapse.
- Phase Four - Ending Well. This phase aims to conclude the treatment well and prepare the transition to outpatient therapy. For this purpose, a written maintenance plan is created, in collaboration with the patient, in which the residual problems are to be faced and the procedures to continue to be used, the strategies and methods to prevent relapse, the ways of organizing life after discharge and post-admission therapy.
The nutritional rehabilitation protocol of the Villa Garda Hospital applied to underweight patients with AN is as follows:
- The weight goal to be achieved is a BMI ≥ 19.
- The expected speed of weight recovery is between 1 and 1.5 kg per week.
- The daily calorie content of the meal plan is established collaboratively with the patient in the first as follows:
- Week 1: Menu A (1,500 kcal)
- Week 2: Menu B (2,000 kcal)
Afterward:
- If the weight increases between 1 and 1.5 kg per week the meal plan is maintained with the same calorie content as the previous week.
- If the weight increases by less than 1 kg per week, the kcal of the food plan is increased by 500 kcal per day. For example, from Menu B to Menu C (2500 kcal) or from Menu C to Menu D (3000 kcal)
- If the weight increases by more than 1.5 kg per week, the kcal of the food plan must be reduced by 250 kcal per day. For example, from Menu C to Menu B / C (2250 kcal)
- When the patient reaches a BMI of 19, the goal of the program is to identify a weight range of 3 kg that it can be without adopting a calorie dietary restriction. In most patients, weight maintenance occurs with a diet between 2000 (Menu B) and 2500 kcal (Menu C).
- Physical activity proposed in the rehabilitation program All patients above the BMI of 15 do two 30-minute sessions per week of calisthenics followed by a physiotherapist.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- A 13-week randomized double-blind placebo-controlled study. Patients will be randomized to EAA supplementation or placebo supplementation upon admission. Randomisation will be carried out by an independent external figure adopting the following stratification: Group 1: BMI <= 15.2 \& age <= 20 Group 2: BMI > 15.2 \& age <= 20 Group 3: BMI <= 15.2 \& age > 20 Group 4: BMI > 15.2 \& age > 20
| Arm | Type | Receives |
|---|---|---|
| EAA supplementation | Experimental | Dietary Supplement: Amino-Ther ProThe EAA blend consists of a complex blend of essential amino acids, including some precursors of neurotransmitters that are important for regulating mood. In particular, phenylalanine, a precursor of tyrosine (non-essential amino acid) is involved in the biosynthesis of catecholamines (noradrenaline, adrenaline, dopamine) and tryptophan is the precursor of serotonin. Furthermore, the amino acids present in the mixture and the precursors of the Krebs cycle (citrate, malate, succinate) are able to stimulate mitochondrial bioenergetics by improving metabolism and muscle function. The EAA blend will be administered orally at 4.5 g twice daily (two sachets of Amino-Ther Pro per day). |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboPlacebo is an isocaloric product containing maltodextrins instead of amino acids (Acquilani et al., 2011). The placebo will be administered orally 4.5 g twice daily. |
Who may qualify
- Ages
- 16 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Diagnosis of anorexia nervosa
- Age between 16 and 50 years
- Written informed consent
Key exclusion criteria (6 listed)
- Schizophrenia or other psychotic disorders
- Diagnosis of bulimia nervosa
- Current and ongoing substance use disorder
- Medical complications capable of hindering the interpretation of the results (e.g. a a medical disease that induces weight loss)
- Presence of physical treatments (including drugs) hindering the interpretation of the results (e.g. chemotherapy for cancer)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Amino-Ther ProFood supplements | Dietary supplement | EAA supplementation |
| PlaceboMaltodextrin | Dietary supplement | Placebo |
Primary outcome
Lean body mass
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Percentage change in patient's lean body mass with weight gain at the end of hospital treatment, measured using the DXA (Prodigy Primo Lunar, A223040501, General Electric Company, Madison. WI 53707-7550, USA-EnCORE TM 2009 (v13.31) software)
5 secondary outcomes
Physical fitness
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Body weight
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Eating disorder psychopathology
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
General psychopathology
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Clinical impairment
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2025.
- Background: PubMed 24060628Dalle Grave R, Calugi S, Conti M, Doll H, Fairburn CG. Inpatient cognitive behaviour therapy for anorexia nervosa: a randomized controlled trial. Psychother Psychosom. 2013;82(6):390-8. doi: 10.1159/000350058. Epub 2013 Sep 20.
- Background: PubMed 26560758El Ghoch M, Pourhassan M, Milanese C, Muller MJ, Calugi S, Bazzani PV, Dalle Grave R. Changes in lean and skeletal muscle body mass in adult females with anorexia nervosa before and after weight restoration. Clin Nutr. 2017 Feb;36(1):170-178. doi: 10.1016/j.clnu.2015.10.006. Epub 2015 Oct 28.
- Background: PubMed 31672329Buondonno I, Sassi F, Carignano G, Dutto F, Ferreri C, Pili FG, Massaia M, Nisoli E, Ruocco C, Porrino P, Ravetta C, Riganti C, Isaia GC, D'Amelio P. From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study. Clin Nutr. 2020 Jul;39(7):2080-2091. doi: 10.1016/j.clnu.2019.10.013. Epub 2019 Oct 18.
- Background: PubMed 29735813Israely M, Ram A, Brandeis R, Alter Z, Avraham Y, Berry EM. A Double Blind, Randomized Cross-Over Trial of Tyrosine Treatment on Cognitive Function and Psychological Parameters in Severe Hospitalized Anorexia Nervosa Patients. Isr J Psychiatry. 2017;54(3):52-58.
- Background: PubMed 12711261Fairburn CG, Cooper Z, Shafran R. Cognitive behaviour therapy for eating disorders: a "transdiagnostic" theory and treatment. Behav Res Ther. 2003 May;41(5):509-28. doi: 10.1016/s0005-7967(02)00088-8.
- Derived from this study: PubMed 36759873Dalle Grave R, Calugi S, Ruocco C, Chimini M, Segala A, Ragni M, Carruba M, Valerio A, Nisoli E. Efficacy and tolerability of a specific blend of amino acids in patients with anorexia nervosa treated in a hospital setting: study protocol for a randomized controlled trial. Trials. 2023 Feb 9;24(1):104. doi: 10.1186/s13063-023-07120-7.
- Individual participant dataSharing planned: No. Individual participant data are not available for privacy reasons
Related trials for Anorexia Nervosa
Not yet recruiting
Be Body Brave: Digital Written Exposure Therapy for Eating Disorders
Eating Disorders
RecruitingObservational study
Speech Groups for Children Living With a Sibling Who Suffers From Anorexia Nervosa
Anorexia Nervosa
Enrolling by invitation
Sleep and Activity For Eating Disorders
Eating Disorders, Anorexia Nervosa
Not yet recruitingObservational study
Biomarkers in EV Associated With Marrow Adiposity in Anorexia
Anorexia Nervosa Restricting Type, Anorexia Nervosa (DSM-IV Revised Criteria)
Active, not recruiting
Targeting Social Function in Anxiety and Eating Disorders
Eating Disorders, Anorexia Nervosa
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Riccardo Dalle Grave, MD principal investigator
Villa Garda Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Amino-Ther Pro in people with Anorexia Nervosa, run by Villa Garda Hospital at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Riccardo Dalle Grave, MD (348 412 0680 ext. +39, rdalleg@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lean body mass (time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05290285, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2025.